Calluna Pharma develops first-in-class monoclonal antibodies targeting upstream disease amplifiers in inflammation and fibrosis. Their clinical-stage pipeline aims to modulate key molecular drivers for improved patient outcomes in diseases with significant unmet medical needs.
Funding
$81.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many inflammatory and fibrotic diseases lack effective therapeutic options due to the complexity of disease pathways. Targeting upstream amplifiers within these pathways presents an opportunity for novel treatments with broad applicability.
Solution
Calluna Pharma is a clinical-stage biotechnology company focused on developing first-in-class antibodies that target upstream disease amplifiers in inflammation and fibrosis. Our scientific approach aims to modulate key molecular drivers of these conditions, offering a new therapeutic modality for diseases with significant unmet medical needs. By focusing on these foundational mechanisms, we are developing a pipeline of antibodies designed to provide improved patient outcomes across a range of fibrotic and inflammatory indications.
Target Audience
Our primary target audience includes pharmaceutical companies seeking licensing or co-development partnerships, as well as clinical researchers and healthcare providers focused on inflammatory and fibrotic diseases.
Features
- Development of novel monoclonal antibodies targeting upstream disease amplifiers in immunology.
- Focus on clinical-stage assets for inflammatory and fibrotic diseases.
- Strategy to address indications with high unmet medical need.
- Platform approach applicable across multiple disease areas.